Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?

被引：0

作者：

Arulananda, Surein

John, Thomas

机构：

[1] Olivia Newton John Canc Res Inst, Canc Immunobiol Lab, Heidelberg, Vic, Australia

[2] Austin Hlth, Dept Med Oncol, Heidelberg, Vic, Australia

[3] La Trobe Univ, Sch Canc Med, Heidelberg, Vic, Australia

来源：

JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 01期

关键词：

CELL LUNG-CANCER; 1ST-LINE TREATMENT; OPEN-LABEL; CHEMOTHERAPY; OSIMERTINIB;

D O I：

10.1016/j.jtho.2019.10.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：12 / 14

页数：3

共 50 条

[41] Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients
Hackner, Klaus
Buder, Anna
Hochmair, Maximilian J.
Strieder, Matthaeus
Grech, Christina
Fabikan, Hannah
Burghuber, Otto C.
Errhalt, Peter
Filipits, Martin
[J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2021, 15
[42] A phase II trial of atezolizumab, bevacizumab, pemetrexed and carboplatin combination for metastatic EGFR-mutated NSCLC after TKI failure
Lam, T. C.
Tsang, K.
Choi, H.
Lee, V. H. F.
Lam, K. O.
Chiang, C. L.
So, T. H.
Chan, W. W.
Nyaw, S. F.
Lim, F.
Lau, J. O.
Chik, J.
Kong, S. F.
Lee, A. W. M.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S1389 - S1389
[43] Disease Monitoring of EGFR-mutated NSCLC Patients Treated with TKIs via EGFR Status in Circulating ctDNA
Li, Y.
Xu, Z.
Wang, S.
Zhu, Y.
Ma, D.
Mu, Y.
Ying, J.
Xing, P.
Li, J.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S445 - S445
[44] Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
Baldacci, Simon
Mazieres, Julien
Tomasini, Pascale
Girard, Nicolas
Guisier, Florian
Audigier-Valette, Clarisse
Monnet, Isabelle
Wislez, Marie
Perol, Maurice
Do, Pascal
Dansin, Eric
Leduc, Charlotte
Leprieur, Etienne Giroux
Moro-Sibilot, Denis
Tulasne, David
Kherrouche, Zoulika
Labreuche, Julien
Cortot, Alexis B.
[J]. ONCOTARGET, 2017, 8 (62) : 105103 - 105114
[45] Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib
Wu, Chen-Te
Hsu, Ping-Chih
Chang, John Wen-Cheng
Chang, Ching-Fu
Huang, Chen-Yang
Yang, Cheng-Ta
Kuo, Chih-Hsi Scott
Fang, Yueh-Fu
Wu, Chiao-En
[J]. THORACIC CANCER, 2023, 14 (25) : 2548 - 2557
[46] A retrospective analysis of locally advanced EGFR-mutated NSCLC patients with durvalumab after chemoradiotherapy
Uchida, Yoshiyasu
Ninomiya, Takashi
Harada, Daijiro
Kozuki, Toshiyuki
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S488 - S488
[47] PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients
Endoh, Hideki
Yatabe, Yasushi
Kosaka, Takayuki
Kuwano, Hiroyuki
Mitsudomi, Tetsuya
[J]. JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (07) : 629 - 634
[48] RETRACTED: Efficacy and Safety of Gefitinib Plus Pemetrexed/ Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study (Retracted Article)
Wang, Rui
Wu, Qiang
[J]. ONCOTARGETS AND THERAPY, 2022, 15 : 31 - 39
[49] Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis
Soo, Ross A.
Cho, Byoung Chul
Kim, Joo-Hang
Ahn, Myung-Ju
Lee, Ki Hyeong
Zimina, Anastasia
Orlov, Sergey
Bondarenko, Igor
Lee, Yun-Gyoo
Lim, Yueh Ni
Lee, Sung Sook
Lee, Kyung-Hee
Pang, Yong Kek
Fong, Chin Heng
Kang, Jin Hyoung
Lim, Chun Sen
Danchaivijitr, Pongwut
Kilickap, Saadettin
Yang, James Chih-Hsin
Arslan, Cagatay
Lee, Hana
Park, Seong Nam
Cicin, Irfan
[J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (12) : 1756 - 1766
[50] Modelling long-term survival outcomes in patients with stage (stg) IBeIIIA EGFR-mutated NSCLC from the ADAURA trial
Cheema, P. K.
Heeg, B.
Dyer, M.
Wu, Y-L.
John, T.
Shepherd, F. A.
de Marinis, F.
Melosky, B.
Samson, B.
Moldaver, D.
Shaw, S.
Miranda, M.
Verhoek, A.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S936 - S937

← 1 2 3 4 5 →